Pharmacotherapeutic management of trigeminal neuropathic pain: an update

Pergolizzi, Joseph V.; Gharibo, Christopher; Magnusson, Peter; Breve, Frank; LeQuang, Jo Ann; Varrassi, Giustino

doi:10.1080/14656566.2022.2087507

Cited by 10 publications

(10 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Etiologies include acute herpes zoster, postherpetic pain, trauma, and others such as MS and space-occupying lesions. Treatment approaches are similar to that of primary trigeminal neuralgia 30 …”

Section: Trigeminal Neuralgiamentioning

confidence: 99%

“…Treatment approaches are similar to that of primary trigeminal neuralgia. 30 GLOSSOPHARYNGEAL NEURALGIA Glossopharyngeal neuralgia is very similar to trigeminal neuralgia in many respects, except for the nerve involved and the presence of some unique symptoms. Overlap with trigeminal neuralgia symptomatology can exist and the Her initial treatment was with a total of 20 units spread in a grid pattern over the areas of greatest pain.…”

Section: Key Pointsmentioning

confidence: 99%

See 1 more Smart Citation

Cranial Neuralgias

Nahas

2024

CONTINUUM: Lifelong Learning in Neurology

View full text Add to dashboard Cite

Objective The cranial neuralgias are relatively rare, but recognizing these syndromes and distinguishing among them is critical to reducing unnecessary pain and disability for affected patients. Despite their distinctive features, cranial neuralgias may go undiagnosed or misdiagnosed for several years. A notable proportion of cranial neuralgia presentations are due to secondary causes and require targeted treatment. The purpose of this article is to review the diagnosis and management of cranial neuralgias encountered in clinical practice. Latest Developments In 2020, the International Classification of Orofacial Pain was released for the first time. Modeled after the International Classification of Headache Disorders, it includes updated terminology for cranial neuralgias. The underlying pathophysiology of the cranial neuralgias is currently believed to be rooted in both peripheral and central nociceptive systems. In addition, a growing number of familial cases are being identified. Recent therapeutic advancements include a better understanding of how to utilize older therapies and procedures more effectively as well as the development of newer approaches. Essential Points Cranial neuralgia syndromes are rare but important to recognize due to their debilitating nature and greater likelihood of having potentially treatable underlying causes. While management options have remained somewhat limited, scientific inquiry is continually advancing the understanding of these syndromes and how best to address them.

show abstract

Section: Trigeminal Neuralgiamentioning

confidence: 99%

Section: Key Pointsmentioning

confidence: 99%

Cranial Neuralgias

Nahas

2024

CONTINUUM: Lifelong Learning in Neurology

View full text Add to dashboard Cite

show abstract

“…Tsymbalyuk et al reported that brivaracetam significantly reduced microglial activation, TNF expression, and leukocyte infiltration into the dorsal horn, in conjunction with reduced NP behaviors in a murine sciatic nerve injury model (Tsymbalyuk et al, 2019). In real-world clinical practice, brivaracetam is sometimes used to relieve TN, either as monotherapy or in combination (Pergolizzi et al, 2022). Since brivaracetam is a ligand of SVP2, and the latter is a potential target of NP (Kenda et al, 2004), it can serve as a mechanism-based pharmacological intervention for SCI-NP.…”

Section: Spinal Cord Injury-related Neuropathic Painmentioning

confidence: 99%

Potential novel therapeutic strategies for neuropathic pain

Zhang

Han

et al. 2023

Front. Mol. Neurosci.

View full text Add to dashboard Cite

PurposeTo explore the potential therapeutic strategies of different types of neuropathic pain (NP) and to summarize the cutting-edge novel approaches for NP treatment based on the clinical trials registered on ClinicalTrials.gov.MethodsThe relevant clinical trials were searched using ClinicalTrials.gov Dec 08, 2022. NP is defined as a painful condition caused by neurological lesions or diseases. All data were obtained and reviewed by the investigators to confirm whether they were related to the current topic.ResultsA total of 914 trials were included in this study. They were divided into painful diabetic neuropathy (PDN), postherpetic neuralgia (PHN), sciatica (SC), peripheral nerve injury-related NP (PNI), trigeminal neuralgia (TN), chemotherapy-induced NP (CINP), general peripheral NP (GPNP) and spinal cord injury NP (SCI-NP). Potential novel therapeutic strategies, such as novel drug targets and physical means, were discussed for each type of NP.ConclusionNP treatment is mainly dominated by drug therapy, and physical means have become increasingly popular. It is worth noting that novel drug targets, new implications of conventional medicine, and novel physical means can serve as promising strategies for the treatment of NP. However, more attention needs to be paid to the challenges of translating research findings into clinical practice.

show abstract

“…The incidence of post-herpetic neuralgia and idiopathic TN are similar. Incidence of TN in the US population was 4.3 per 100,000, with a considerably greater (3). Stage estimates that the annual predictable incidence of TN increases from 4 to 12.5 per 100,000 people (4).…”

Section: Introductionmentioning

confidence: 99%

“…Avariety of mechanisms, such as peripheral root pathology (compression or traction), dysfunction of the brainstem, basal ganglia, and cortical mechanisms of pain modulation, and dysfunction of peripheral root pathology are all potential contributors, neurovascular conflict is the most widely accepted theory (5).A characteristic of TN is recurrent attacks of lancinating pain in the region where the trigeminal nerve (3). The pain normally last a few seconds, but can happen repeatedly in a short period of time.…”

Section: Introductionmentioning

confidence: 99%

Comparison of carbamazepine alone and in combination with baclofen in trigeminal neuralgia

Rehman

Umar

Zafar

et al. 2022

ijhs

View full text Add to dashboard Cite

Introduction: Trigeminal neuralgia is a type of neuropathic facial pain that is characterized by unilateral paroxysmal pain that affects one or more trigeminal nerve divisions and is brought on by unimportant stimuli. People over the age of 40 are more likely to get it, and women are more frequently affected than males. Trigeminal neuralgia has been treated with a variety of drugs, including carbamazepine, oxcarbazepine, baclofen, lamotrigine, levetiracetam, gabapentin, sodium valproate, botulinum toxin-A injection, and surgical. OBJECTIVES: The current study's objective was to assess the efficacy of carbamazepine in treating trigeminal neuralgia in individuals both on its own and in combination with baclofen. METHODS: A randomized control trial was conductedat Khyber College of Dentistry and Peshawar Dental College among the patients of trigeminal neuralgia presenting to OPD. Total 60patients were randomly selected into two groups, each group had 30 patients.Carbamazepine was given to the Group A in the dose range of 300-600mg TDSwhereas, Carbamazepine 300mg TDS along with Baclofen in the dose range of 10-20 mg B.D was given to Group B. The two groups were given the drugs for a period of thirty days. The data was collected through a self-structuredquestionnaire.

show abstract

Pharmacotherapeutic management of trigeminal neuropathic pain: an update

Cited by 10 publications

References 96 publications

Cranial Neuralgias

Cranial Neuralgias

Potential novel therapeutic strategies for neuropathic pain

Comparison of carbamazepine alone and in combination with baclofen in trigeminal neuralgia

Contact Info

Product

Resources

About